RenalPhotoGraph.com – Continuous Quality Improvement System (2007)
One of the world’s foremost biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Founded in Boston in 1981, Genzyme has grown from a small start-up to a diversified enterprise with annual revenues exceeding $3 billion and more than 9,500 employees in locations spanning the globe.
With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company’s products and services are focused on rare inherited disorders, kidney disease, orthopaedics, transplant, cancer, and diagnostic testing. Genzyme’s commitment to innovation continues today with a substantial research and development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.
The PhotoGraph web-based clinical analysis system is a multi-lingual data entry and reporting application used by clinics in Canada to enter and report on information for patients with Chronic Kidney Disease (CKD) on hemodialysis. It is a Continuous Quality Improvement application whose primary focus is to improve the care for CKD patients across the country. The information is used by clinics for real-time comparison purposes and reporting.
The major functions of PhotoGraph are listed below:
Data entry of patient lab values and medications
Interface for patient information from existing clinic systems (i.e. NephroCare, Promise, Meditech)
Dynamically add new lab or medication parameters to be collected, and associate these parameters with K/DOQI, DOPPS or other guidelines
Produce an anonymous patient report card as something the patient can take home
Produce an extensive array of reports and PowerPoint presentations based on cross-country real-time data
There is clear evidence that mineral and bone metabolism disease have serious consequences on the prognosis for patients with chronic kidney disease.
The K/DOQI Guidelines issued by a group of international experts and published in 2003 by the National Kidney Foundation were the product of a systematic review of the literature published as of January 1, 2001. These practical recommendations were developed to suggest an integrated clinical approach to complex phosphorus and calcium metabolism abnormalities.
The K/DOQI recommendations set the upper and lower limits for biological parameters when monitoring bone and mineral metabolism which include: serum levels of calcium, phosphorus, calcium-phosphorus product and parathyroid hormone, and which put forward recommendations on therapeutic management depending on other abnormalities observed.
The solution allows Genzyme to collect a dynamic array of medications, non-identifying patient data, and lab values with ability to track a patient’s progression over time (either in tabular or chart format). The data entry section allows for the entry of numerical, formula-based, textual, drop-down, and yes/no type fields.
Parameter Search Capability
The system allows the user to query on a number of different factors including patients meeting certain threshold guidelines for specific lab values, patients taking certain medications, patient demographic details, etc.
Administration and Multi-tiered Access
The system allows for administration on various items, including:
The system also consists of an array of multiple users (Clinic Administrators, Clinic Users, Sales, etc.) each with varying levels of access to certain data and screens within PhotoGraph.
The system allows the user to create his/her own charts through a reporting wizard, or choose from a number of standard reports. These reports illustrate anonymous patient tracking data and aggregated patient data as it compares to various guidelines.
PhotoGraph allows the user to upload data in various formats, and provides a wizard to walk the user through the upload process. This data comes predominantly from existing clinic systems and reduces the need for dual entry.
For more information about this solution, please contact email@example.com